A 48-year-old woman with hepatitis C virus (HCV) infection is found to have evidence of portal hypertension on imaging. She is asymptomatic with normal synthetic function. Which investigation is most appropriate to assess the degree of hepatic fibrosis and guide decisions regarding antiviral therapy and surveillance?

## Non-Invasive Assessment of Hepatic Fibrosis in HCV **Key Point:** Transient elastography (FibroScan) is the first-line non-invasive investigation for assessing the degree of hepatic fibrosis in patients with chronic HCV. It has high sensitivity and specificity for detecting cirrhosis (F4) and advanced fibrosis (F3), and guides antiviral therapy decisions and surveillance protocols. ### Advantages of Transient Elastography 1. **Non-invasive:** No risk of bleeding, infection, or sampling error 2. **Rapid and reproducible:** Can be performed in outpatient setting; results available immediately 3. **High accuracy for advanced disease:** Sensitivity ~90% and specificity ~85% for cirrhosis (F4) 4. **Prognostic value:** Liver stiffness measurement (LSM) correlates with portal hypertension risk and prognosis 5. **Guides management:** Determines need for surveillance (varices screening, HCC surveillance) and timing of antiviral therapy ### Controlled Attenuation Parameter (CAP) The CAP module measures hepatic steatosis simultaneously, which is important in: - Assessing metabolic dysfunction-associated fatty liver disease (MAFLD) overlap - Predicting treatment response in HCV - Risk stratification for HCC **High-Yield:** Current guidelines (AASLD, EASL, WHO) recommend transient elastography as the preferred non-invasive method for fibrosis staging in chronic HCV, particularly to identify patients with cirrhosis who require HCC surveillance. ### Comparison of Fibrosis Assessment Methods | Method | Advantages | Limitations | Role | |---|---|---|---| | **Transient elastography** | Non-invasive, rapid, reproducible, high accuracy for F3–F4 | Operator-dependent, unreliable in ascites/obesity, cannot assess etiology | First-line for fibrosis staging | | **Serum biomarkers** (hyaluronic acid, PIIINP, FibroTest) | Objective, no operator dependence | Moderate accuracy for intermediate fibrosis (F2), affected by inflammation | Adjunctive, useful when elastography unavailable | | **Liver biopsy** | Gold standard, allows histological grading and etiology assessment | Invasive, sampling error, patient morbidity | Reserved for diagnostic uncertainty or need for etiology confirmation | | **Doppler ultrasound** | Detects portal hypertension signs | Does not quantify fibrosis; non-specific | Complements elastography; assesses hemodynamic consequences | **Clinical Pearl:** In this asymptomatic HCV patient with portal hypertension on imaging, transient elastography will: - Quantify fibrosis stage (F0–F4) - Determine if cirrhosis is present (which mandates HCC surveillance every 6 months) - Guide timing and urgency of antiviral therapy - Assess steatosis burden (CAP) **Mnemonic: FEST** — **F**ibroScan (transient elastography), **E**asy to perform, **S**ensitive for **S**evere fibrosis/cirrhosis, **T**iming of treatment. **Tip:** Remember that transient elastography is superior to serum biomarkers for distinguishing cirrhosis from advanced fibrosis, which is critical for surveillance decisions in HCV.